SG11201900712SA - Memantine transdermal delivery systems - Google Patents
Memantine transdermal delivery systemsInfo
- Publication number
- SG11201900712SA SG11201900712SA SG11201900712SA SG11201900712SA SG11201900712SA SG 11201900712S A SG11201900712S A SG 11201900712SA SG 11201900712S A SG11201900712S A SG 11201900712SA SG 11201900712S A SG11201900712S A SG 11201900712SA SG 11201900712S A SG11201900712S A SG 11201900712SA
- Authority
- SG
- Singapore
- Prior art keywords
- memantine
- international
- california
- salt
- transdermal delivery
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
140 160 0 20 40 60 8C 100 Time (hr) FIG. 2 ac 2 tlJ C C ro E (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 01 February 2018 (01.02.2018) WIP0 I PCT onion °nolo III 1101 °nom° 1 ois (10) International Publication Number WO 2018/022818 Al (51) International Patent Classification: A61K 31/13 (2006.01) A61P 25/28 (2006.01) A61K 9/70 (2006.01) A61P 9/10 (2006.01) A61P 25/00 (2006.01) (21) International Application Number: PCT/US2017/044051 (22) International Filing Date: 26 July 2017 (26.07.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/367,502 27 July 2016 (27.07.2016) US 62/423,133 16 November 2016 (16.11.2016) US 62/444,745 10 January 2017 (10.01.2017) US 62/444,763 10 January 2017 (10.01.2017) US 62/457,791 10 February 2017 (10.02.2017) US 62/457,794 10 February 2017 (10.02.2017) US 62/504,391 10 May 2017 (10.05.2017) US (71) Applicant: CORIUM INTERNATIONAL, INC. [US/US]; 235 Constitution Drive, Menlo Park, California 94025 (US). (72) Inventors: LEE, Eun Soo; 2575 Hampton Avenue, Red- wood City, California 94061 (US). SINGH, Parminder; 5504 Alvelais Drive, Union City, California 94587 (US). SAGI, Appala; 2025 California Street #42, Mountain View, California 94040 (US). JAIN, Amit K.; 825 Carino Terrace, Milpitas, California 95035 (US). (74) Agent: MOHR, Judy M. et al.; McDermott Will & Emery LLP, 500 North Capitol Street, NM., Washington, District of Columbia 20001-1531 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, = (54) Title: MEMANTINE TRANSDERMAL DELIVERY SYSTEMS - Memantine salt, sodium bicarb -c - Memantine free base 40 —0-- Memantine salt, no sodium bicarb a) A Memantine salt, altemative to sodium bicarb (57) : Transdermal delivery systems for the systemic delivery of memantine are described, wherein the system comprises a drug reservoir layer and an adhesive layer, optionally together with one or more intermediate and/or supporting layers, wherein the drug reservoir layer comprises an acrylate polymer or copolymer, a permeation enhancer, a carrier, and memantine base generated in situ by reaction of a memantine salt and an alkaline salt. Compositions and kits comprising the various components, e.g., drug reservoir and/or adhesive compositions are described. Methods relating to treatment of CNS disorders, e.g., Alzheimer's disease and/or dementia, using the aforementioned transdermal delivery devices and/or compositions are also described. [Continued on next page] WO 2018/022818 Al IMEDIMOMMIDIRE10101011010HOHHOHOMEMNIE HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3))
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662367502P | 2016-07-27 | 2016-07-27 | |
US201662423133P | 2016-11-16 | 2016-11-16 | |
US201762444763P | 2017-01-10 | 2017-01-10 | |
US201762444745P | 2017-01-10 | 2017-01-10 | |
US201762457794P | 2017-02-10 | 2017-02-10 | |
US201762457791P | 2017-02-10 | 2017-02-10 | |
US201762504391P | 2017-05-10 | 2017-05-10 | |
PCT/US2017/044051 WO2018022818A1 (en) | 2016-07-27 | 2017-07-26 | Memantine transdermal delivery systems |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201900712SA true SG11201900712SA (en) | 2019-02-27 |
Family
ID=59523315
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201900712SA SG11201900712SA (en) | 2016-07-27 | 2017-07-26 | Memantine transdermal delivery systems |
Country Status (11)
Country | Link |
---|---|
US (1) | US10945968B2 (en) |
EP (1) | EP3490544A1 (en) |
JP (2) | JP7071958B2 (en) |
KR (1) | KR102508993B1 (en) |
CN (1) | CN109789113A (en) |
AU (1) | AU2017301929B2 (en) |
CA (1) | CA3032103A1 (en) |
MX (1) | MX2019001104A (en) |
RU (1) | RU2764764C2 (en) |
SG (1) | SG11201900712SA (en) |
WO (1) | WO2018022818A1 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109922796B (en) | 2016-06-23 | 2023-04-07 | 考里安有限责任公司 | Adhesive matrix with hydrophilic and hydrophobic domains and therapeutic agents |
US10300025B2 (en) | 2016-07-27 | 2019-05-28 | Corium, Inc. | Donepezil transdermal delivery system |
AU2017301929B2 (en) | 2016-07-27 | 2023-03-02 | Corium Pharma Solutions, Inc. | Memantine transdermal delivery systems |
WO2018160613A1 (en) * | 2017-02-28 | 2018-09-07 | Temple University-Of The Commonwealth System Of Higher Education | Novel econazole nitrate medical patch and methods of use thereof |
WO2019126531A1 (en) | 2017-12-20 | 2019-06-27 | Corium, Inc. | Transdermal adhesive composition comprising a volatile liquid therapeutic agent having low melting point |
US20220241216A1 (en) * | 2019-07-09 | 2022-08-04 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system comprising an active agent-containing layer comprising an acrylic polymer and a skin contact layer comprising a silicone gel adhesive |
CN115957200A (en) * | 2023-02-23 | 2023-04-14 | 广州新济药业科技有限公司 | Memantine transdermal patch and preparation method thereof |
Family Cites Families (123)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3391142A (en) | 1966-02-09 | 1968-07-02 | Lilly Co Eli | Adamantyl secondary amines |
NL134681C (en) | 1966-04-26 | |||
US3546141A (en) | 1966-08-08 | 1970-12-08 | Mc Donnell Douglas Corp | Phosphorus-nitrogen polymers and process |
ES413944A1 (en) | 1972-04-20 | 1976-06-01 | Merz & Co | Drugs or medicines for influencing the central nervous system |
DE2856393C2 (en) | 1978-12-27 | 1983-04-28 | Merz + Co GmbH & Co, 6000 Frankfurt | Medicines used to treat Parkinson's disease |
US4752478A (en) * | 1984-12-17 | 1988-06-21 | Merck & Co., Inc. | Transdermal system for timolol |
DE3572485D1 (en) | 1984-12-22 | 1989-09-28 | Thomae Gmbh Dr K | Tetrahydro-benzothiazoles, their production and their use as intermediates or drugs |
US4880633A (en) | 1986-03-12 | 1989-11-14 | Merck & Co., Inc. | Transdermal drug delivery system |
FI95572C (en) | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Process for the preparation of a medicament useful as a piperidine derivative or its pharmaceutical salt |
US4837027A (en) | 1987-11-09 | 1989-06-06 | Alza Corporation | Transdermal drug delivery device |
US4781924A (en) | 1987-11-09 | 1988-11-01 | Alza Corporation | Transdermal drug delivery device |
US4849224A (en) | 1987-11-12 | 1989-07-18 | Theratech Inc. | Device for administering an active agent to the skin or mucosa |
US5026556A (en) | 1988-11-10 | 1991-06-25 | Norwich Eaton Pharmaceuticals, Inc. | Compositions for the transdermal delivery of pharmaceutical actives |
DE58905637D1 (en) | 1989-04-14 | 1993-10-21 | Merz & Co Gmbh & Co | Use of adamantane derivatives for the prevention and treatment of cerebral ischemia. |
DE69010076T2 (en) * | 1989-05-25 | 1994-12-08 | Takeda Chemical Industries Ltd | Transdermal therapeutic agent. |
US5252588A (en) | 1990-04-27 | 1993-10-12 | Sekisui Kagaku Kogyo Kabushiki Kaisha | Percutaneously absorbable crosslinked polyvinylpyrrolidone eperisone or tolperisone preparation |
AU652952B2 (en) | 1990-07-23 | 1994-09-15 | Alza Corporation | Oral osmotic device for delivering nicotine |
IT1243745B (en) * | 1990-10-17 | 1994-06-21 | Vectorpharma Int | TRANSDERMAL THERAPEUTIC COMPOSITIONS CONTAINING DRUG AND / OR PROMOTING AGENT OF THE SKIN ABSORPTION SUPPORTED ON MICROPOROUS PARTICLES AND POLYMERIC MICROSPHERES AND THEIR PREPARATION. |
US5614560A (en) | 1991-04-04 | 1997-03-25 | Children's Medical Center Corporation | Method of preventing NMDA receptor-mediated neuronal damage |
US5123900A (en) | 1991-08-16 | 1992-06-23 | Bertek, Inc. | Moisture permeable double disk |
JPH06199659A (en) | 1992-10-28 | 1994-07-19 | Hisamitsu Pharmaceut Co Inc | Apparatus for percutaneous treatment |
US5424077A (en) | 1993-07-13 | 1995-06-13 | Church & Dwight Co., Inc. | Co-micronized bicarbonate salt compositions |
CA2198390C (en) | 1994-09-14 | 2009-08-11 | James E. Garbe | Matrix for transdermal drug delivery |
US5635203A (en) | 1994-09-29 | 1997-06-03 | Alza Corporation | Transdermal device having decreased delamination |
CA2208132A1 (en) | 1994-12-21 | 1996-06-27 | Theratech, Inc. | Transdermal delivery system with adhesive overlay and peel seal disc |
WO1996040087A2 (en) | 1995-06-07 | 1996-12-19 | Cygnus, Inc. | Pressure sensitive acrylate adhesive composition cross-linked with aluminum acetylacetonate and containing a drug having a reactive aromatic hydroxyl group |
DE19531342B4 (en) | 1995-08-25 | 2007-11-29 | Merz Pharma Gmbh & Co. Kgaa | Use of aminoadamantane compounds as immunoregulators |
US6929801B2 (en) | 1996-02-19 | 2005-08-16 | Acrux Dds Pty Ltd | Transdermal delivery of antiparkinson agents |
US6512010B1 (en) | 1996-07-15 | 2003-01-28 | Alza Corporation | Formulations for the administration of fluoxetine |
US5958919A (en) | 1996-09-20 | 1999-09-28 | Washington University | Treatment of presymptomatic alzheimer's disease to prevent neuronal degeneration |
ES2191834T3 (en) | 1996-10-24 | 2003-09-16 | Alza Corp | AGENTS THAT FACILITATE THE PERMEATION AND DESTINATIONS FOR COMPOSITIONS, DEVICES AND PROCEDURES OF TRANSDERMAL CONTRIBUTION OF DRUGS. |
US5866585A (en) | 1997-05-22 | 1999-02-02 | Synchroneuron, Llc | Methods of treating tardive dyskinesia using NMDA receptor antagonists |
US6193993B1 (en) | 1998-03-03 | 2001-02-27 | Eisai Co., Ltd. | Suppository containing an antidementia medicament |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6383471B1 (en) | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
US6562368B2 (en) | 1999-12-16 | 2003-05-13 | Dermatrends, Inc. | Transdermal administration of oxybutynin using hydroxide-releasing agents as permeation enhancers |
US20020192243A1 (en) | 1999-12-16 | 2002-12-19 | Tsung-Min Hsu | Transdermal and topical administration of drugs for the treatment of Alzheimer's disease using basic enhancers |
US6455066B1 (en) | 2000-03-10 | 2002-09-24 | Epicept Corporation | Intradermal-penetration agents for topical local anesthetic administration |
US7276249B2 (en) | 2002-05-24 | 2007-10-02 | Elan Pharma International, Ltd. | Nanoparticulate fibrate formulations |
AU1436402A (en) | 2000-11-06 | 2002-05-15 | Samyang Corp | Transdermal drug delivery system with improved water absorbability and adhesion properties |
ATE438418T1 (en) | 2001-05-01 | 2009-08-15 | Av Topchiev Inst Petrochemical | HYDROGEL COMPOSITIONS |
WO2003015713A2 (en) | 2001-08-20 | 2003-02-27 | Maiken Nedergaard | Treatment of glial tumors with glutamate antagonists |
CA2459399C (en) | 2001-09-04 | 2009-06-30 | Trommsdorff Gmbh & Co. Kg Arzneimittel | Plaster for the treatment of dysfunctions and disorders of nails, comprising sertaconazole |
US7273619B2 (en) | 2002-01-17 | 2007-09-25 | Samyang Corporation | Transdermal composition of an antivomiting agent |
WO2004037234A2 (en) | 2002-10-24 | 2004-05-06 | Merz Pharma Gmbh & Co. Kgaa | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors |
MXPA06003316A (en) | 2003-10-10 | 2006-06-08 | Antares Pharma Ipl Ag | Transdermal pharmaceutical formulation for minimizing skin residues. |
EP1682109B1 (en) | 2003-10-22 | 2008-10-15 | Merz Pharma GmbH & Co. KGaA | The use of 1-aminocyclohexane derivatives to modify deposition of fibrillogenic as peptides in amyloidopathies |
EP1684806B1 (en) | 2003-11-21 | 2008-06-25 | Memory Pharmaceuticals Corporation | Compositions comprising l-type calcium channel blockers and cholinesterase inhibitors |
US7176185B2 (en) | 2003-11-25 | 2007-02-13 | Tsrl, Inc. | Short peptide carrier system for cellular delivery of agent |
KR20130006523A (en) | 2004-02-17 | 2013-01-16 | 트랜스셉트 파마슈티칼스, 인코포레이티드 | Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof |
US7670838B2 (en) | 2004-05-24 | 2010-03-02 | The Board Of Trustees Of The Leland Stanford Junior University | Coupling of excitation and neurogenesis in neural stem/progenitor cells |
US20080038328A1 (en) | 2004-05-28 | 2008-02-14 | Naruhito Higo | Pasting Preparation |
TW200616608A (en) | 2004-07-09 | 2006-06-01 | Forest Laboratories | Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients |
US8252321B2 (en) | 2004-09-13 | 2012-08-28 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
WO2006044206A2 (en) | 2004-10-08 | 2006-04-27 | Noven Pharmaceuticals, Inc. | Transdermal drug delivery device including an occlusive backing |
ATE413166T1 (en) | 2004-11-22 | 2008-11-15 | Hisamitsu Pharmaceutical Co | TRANSDERMAL PLASTER CONTAINING A MELTING POINT-LOWERING EXCIPIENT |
US7619007B2 (en) | 2004-11-23 | 2009-11-17 | Adamas Pharmaceuticals, Inc. | Method and composition for administering an NMDA receptor antagonist to a subject |
US20060205822A1 (en) | 2004-12-22 | 2006-09-14 | Forest Laboratories, Inc. | 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect |
SI1836157T1 (en) | 2005-01-11 | 2009-12-31 | Teva Pharm Fine Chemicals Srl | Process for the preparation of 1-amino-3,5-dimethyladamantane hydrochloride |
WO2006082728A1 (en) | 2005-02-04 | 2006-08-10 | Hisamitsu Pharmaceutical Co., Inc. | Transdermal absorption patch |
CA2604052C (en) | 2005-04-06 | 2014-07-08 | Adamas Pharmaceuticals, Inc. | Methods and compositions for the treatment of cns-related conditions |
US7888422B2 (en) | 2005-11-09 | 2011-02-15 | Mylan Technologies Inc. | Long-wearing removable pressure sensitive adhesive |
ATE468219T1 (en) | 2006-03-28 | 2010-06-15 | Amcor Flexibles Transpac B V B | FOR AROMA COMPOUNDS, IMPERMEABLE, HALOGEN-FREE MULTI-LAYER FILM |
IL175338A0 (en) | 2006-05-01 | 2006-09-05 | Biota Ltd | Orally administrable films and preparation thereof |
CN101460156B (en) * | 2006-05-08 | 2011-06-08 | 帝国制药株式会社 | Tansdermally absorbable preparation comprising anti-dementia agent |
JP5097359B2 (en) | 2006-05-09 | 2012-12-12 | 久光製薬株式会社 | Donepezil transdermal preparation |
WO2007132476A2 (en) * | 2006-05-15 | 2007-11-22 | Matrix Laboratories Limited | A process for the preparation of memantine hydrochloride |
US9248104B2 (en) | 2006-08-17 | 2016-02-02 | Core Tech Solutions, Inc. | Transdermal methods and systems for treating Alzheimer's disease |
US20080107719A1 (en) | 2006-11-08 | 2008-05-08 | Sukhon Likitlersuang | Transdermal drug delivery system |
RU2452474C2 (en) | 2006-12-01 | 2012-06-10 | Нитто Денко Корпорейшн | Stabilised adhesive composition containing donepezil |
KR20090086565A (en) | 2006-12-01 | 2009-08-13 | 닛토덴코 가부시키가이샤 | Skin adhesive preparation comprising stabilized donepezil |
KR101408488B1 (en) | 2006-12-01 | 2014-06-17 | 닛토덴코 가부시키가이샤 | Method for prevention of discoloration with time of donepezil-containing skin adhesive preparation |
JP5403948B2 (en) * | 2007-06-07 | 2014-01-29 | 久光製薬株式会社 | Memantine-containing transdermal absorption preparation |
WO2009009649A1 (en) | 2007-07-10 | 2009-01-15 | Agile Therapeutics, Inc. | Dermal delivery device with in situ seal |
JP2009203213A (en) | 2008-02-28 | 2009-09-10 | Kosumedei Seiyaku Kk | Percutaneous absorption pharmaceutical composition |
DE102008013701A1 (en) * | 2008-03-11 | 2009-09-17 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system with stabilized membrane |
KR101454362B1 (en) | 2008-03-24 | 2014-10-23 | 아이큐어 주식회사 | Percutaneous absorption preparations for the treatment of dementia containg donepezil as an active ingredient |
US20090291127A1 (en) | 2008-05-21 | 2009-11-26 | Jianye Wen | Transdermal anti-dementia active agent formulations and methods for using the same |
AR074062A1 (en) | 2008-10-31 | 2010-12-22 | Lexicon Pharmaceuticals Inc | S1P RECEIVER AGONISTS FOR THE TREATMENT OF BRAIN MALARIA AND PHARMACEUTICAL FORM |
US20100178037A1 (en) | 2009-01-12 | 2010-07-15 | Te-Wei Chen | Display apparatus, video generation apparatus, and method thereof |
EP2387394B1 (en) | 2009-01-14 | 2018-05-02 | Corium International, Inc. | Transdermal administration of tamsulosin |
KR101725832B1 (en) | 2009-05-01 | 2017-04-11 | 히사미쓰 세이야꾸 가부시키가이샤 | Transdermal preparation |
CN102630160B (en) | 2009-09-16 | 2014-05-07 | 株式会社三养生物制药 | Transdermal delivery system, method for manufacturing the same, and transdermal delivery method using the system |
RU2545696C2 (en) | 2009-10-21 | 2015-04-10 | Тейкоку Сейяку Ко., Лтд. | Transdermally absorbable formulation containing donepezil |
CN102048678A (en) | 2009-10-30 | 2011-05-11 | 北京隆旗生物科技有限公司 | Transdermal absorption preparation of oxybutynin as well as preparation method and medication application thereof |
GB0921481D0 (en) | 2009-12-08 | 2010-01-20 | Vectura Ltd | Process and product |
JP2012236773A (en) | 2009-12-16 | 2012-12-06 | Goto Takeshi | Transdermally absorbable preparation of anti-dementia drug |
EP2519225B1 (en) | 2009-12-30 | 2015-03-25 | Novartis AG | Melt extruded nicotine thin strips |
US20110244023A1 (en) | 2010-03-30 | 2011-10-06 | Phosphagenics Limited | Transdermal delivery patch |
JP5665861B2 (en) | 2010-04-28 | 2015-02-04 | 久光製薬株式会社 | Donepezil containing transdermal absorption preparation |
WO2011146583A2 (en) | 2010-05-19 | 2011-11-24 | Elan Pharma International Limited | Nanoparticulate cinacalcet formulations |
RU2578971C2 (en) * | 2010-06-17 | 2016-03-27 | Лтс Ломанн Терапи-Системе Аг | Transdermal administration of memantine |
DE102010024105A1 (en) * | 2010-06-17 | 2011-12-22 | Grünenthal GmbH | Transdermal administration of memantine |
US20140370076A1 (en) | 2010-06-30 | 2014-12-18 | Nal Pharmaceuticals, Ltd. | Transdermal drug delivery system containing donepezil |
RU2013121270A (en) * | 2010-10-12 | 2014-11-20 | Серекор Инк. | COMPOUNDS AGAINST COUGH CONTAINING MEMANTINE |
WO2012057212A1 (en) * | 2010-10-28 | 2012-05-03 | 久光製薬株式会社 | Percutaneous absorption type formulation |
JP5699554B2 (en) | 2010-11-11 | 2015-04-15 | 富士通株式会社 | Vector processing circuit, instruction issue control method, and processor system |
WO2012084969A1 (en) | 2010-12-22 | 2012-06-28 | Hexal Ag | Adhesive composition containing rotigotine and transdermal therapeutic system comprising the adhesive composition |
TWI433904B (en) | 2011-01-12 | 2014-04-11 | Taiwan Biotech Co Ltd | Donepezil transdermal patch |
US8673338B2 (en) | 2011-07-29 | 2014-03-18 | Massachusetts Eye And Ear Infirmary | Methods of delivering pharmaceutical agents |
JP5820207B2 (en) * | 2011-09-13 | 2015-11-24 | 日東電工株式会社 | Transdermal absorption enhancing composition and patch preparation |
KR101239150B1 (en) | 2012-02-28 | 2013-03-06 | 에스케이케미칼주식회사 | Donepezil-containing transdermal delivery system and process for preparing the same |
US20140256690A1 (en) | 2013-03-08 | 2014-09-11 | Agile Therapeutics, Inc. | Contraceptive method |
WO2014174564A1 (en) | 2013-04-22 | 2014-10-30 | 祐徳薬品工業株式会社 | Adhesive patch drug formulation of transdermal absorption type containing memantine |
JP5415645B1 (en) | 2013-06-28 | 2014-02-12 | 久光製薬株式会社 | Manufacturing method of patch, patch and package |
US10772871B2 (en) | 2013-10-07 | 2020-09-15 | Teikoku Pharma Usa, Inc. | Dexmedetomidine transdermal delivery devices and methods for using the same |
KR101820330B1 (en) | 2013-10-11 | 2018-01-19 | 테이코쿠 팔마 유에스에이, 인코포레이티드 | Topical sphingosine-1-phosphate receptor agonist formulations and methods of using the same |
KR101485822B1 (en) | 2014-01-22 | 2015-01-23 | 주식회사 대웅제약 | Transdermal drug delivery system comprising donepezil or its salt |
JP2015151370A (en) | 2014-02-14 | 2015-08-24 | 日東電工株式会社 | patch preparation |
JP2017519837A (en) | 2014-06-24 | 2017-07-20 | カット トランスダーマルズ エルエルシー | Transdermal delivery system |
EP3169318B1 (en) | 2014-07-18 | 2020-04-01 | Buzzz Pharmaceuticals Limited | Abuse deterrent opiod/opiod-antagonist transdermal patch |
EP3189854B1 (en) * | 2014-09-03 | 2020-04-29 | Nitto Denko Corporation | Vaccine composition for transdermal or transmucosal administration |
WO2016046675A1 (en) | 2014-09-28 | 2016-03-31 | Mohan M Alapati | Compositions and methods for the treatment of neurological diseases |
CN113797180A (en) | 2014-12-18 | 2021-12-17 | Icure药品株式会社 | Percutaneous absorption preparation containing donepezil as active ingredient |
CN108135860A (en) | 2015-06-22 | 2018-06-08 | 考里安国际公司 | Include the transdermal adhesive composition of slightly solubility therapeutic agent |
US20180207108A1 (en) | 2015-07-27 | 2018-07-26 | Hisamitsu Pharmaceutical Co., Inc. | Method for Manufacturing Asenapine-Containing Patch |
SG11201805570WA (en) * | 2015-12-30 | 2018-07-30 | Corium Int Inc | Systems and methods for long term transdermal administration |
CN105693556A (en) | 2016-03-01 | 2016-06-22 | 巴斯特医药科技(常州)有限公司 | Transformation method for rivastigmine tartrate and patch prepared from product of rivastigmine tartrate |
CN109922796B (en) | 2016-06-23 | 2023-04-07 | 考里安有限责任公司 | Adhesive matrix with hydrophilic and hydrophobic domains and therapeutic agents |
US10300025B2 (en) | 2016-07-27 | 2019-05-28 | Corium, Inc. | Donepezil transdermal delivery system |
AU2017301929B2 (en) | 2016-07-27 | 2023-03-02 | Corium Pharma Solutions, Inc. | Memantine transdermal delivery systems |
US10016372B2 (en) | 2016-07-27 | 2018-07-10 | Corium International, Inc. | Transdermal delivery systems with pharmacokinetics bioequivalent to oral delivery |
MX2020000651A (en) | 2017-07-26 | 2020-07-29 | Corium Inc | Transdermal delivery system with a microporous membrane having solvent-filled pores. |
-
2017
- 2017-07-26 AU AU2017301929A patent/AU2017301929B2/en not_active Ceased
- 2017-07-26 WO PCT/US2017/044051 patent/WO2018022818A1/en active Search and Examination
- 2017-07-26 CN CN201780059395.4A patent/CN109789113A/en active Pending
- 2017-07-26 CA CA3032103A patent/CA3032103A1/en active Pending
- 2017-07-26 KR KR1020197005636A patent/KR102508993B1/en active IP Right Grant
- 2017-07-26 US US15/660,929 patent/US10945968B2/en active Active
- 2017-07-26 EP EP17749060.4A patent/EP3490544A1/en active Pending
- 2017-07-26 JP JP2019504002A patent/JP7071958B2/en active Active
- 2017-07-26 RU RU2019105280A patent/RU2764764C2/en active
- 2017-07-26 SG SG11201900712SA patent/SG11201900712SA/en unknown
- 2017-07-26 MX MX2019001104A patent/MX2019001104A/en unknown
-
2022
- 2022-04-14 JP JP2022066862A patent/JP2022087276A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US10945968B2 (en) | 2021-03-16 |
CN109789113A (en) | 2019-05-21 |
RU2019105280A3 (en) | 2020-12-03 |
JP2022087276A (en) | 2022-06-09 |
WO2018022818A1 (en) | 2018-02-01 |
US20180028466A1 (en) | 2018-02-01 |
JP2019522025A (en) | 2019-08-08 |
AU2017301929A1 (en) | 2019-02-14 |
CA3032103A1 (en) | 2018-02-01 |
KR102508993B1 (en) | 2023-03-10 |
RU2764764C2 (en) | 2022-01-21 |
EP3490544A1 (en) | 2019-06-05 |
MX2019001104A (en) | 2019-10-02 |
RU2019105280A (en) | 2020-08-27 |
AU2017301929B2 (en) | 2023-03-02 |
JP7071958B2 (en) | 2022-05-19 |
KR20190032551A (en) | 2019-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201900712SA (en) | Memantine transdermal delivery systems | |
SG11201900692WA (en) | Donepezil transdermal delivery system | |
SG11201906891RA (en) | Methods for the administration of certain vmat2 inhibitors | |
SG11201805570WA (en) | Systems and methods for long term transdermal administration | |
SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201901445TA (en) | A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid | |
SG11201908012SA (en) | Cyclic sulfamide compounds and methods of using same | |
SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
SG11201901006RA (en) | Systems and methods for enhanced organizational transparency using a credit chain | |
SG11201811150WA (en) | Ev-mediated delivery of binding protein-small molecule conjugates | |
SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201807421TA (en) | The use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors | |
SG11201908075UA (en) | A microneedle device | |
SG11201408186TA (en) | Pyridinone and pyridazinone derivatives | |
SG11201804312RA (en) | Microbubble-chemotherapeutic agent complex for sonodynamic therapy | |
SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
SG11201909083UA (en) | Piperidines as covalent menin inhibitors | |
SG11201900443VA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201908743SA (en) | Methods and compositions for modulation of immune cells | |
SG11201804721SA (en) | Modulators of complement activity |